These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32703777)

  • 1. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Souleymane MB; Piubello A; Lawan IM; Hassane-Harouna S; Assao-Neino MM; Soumana A; Hamidou-Harouna Z; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Schwoebel V; Mamadou S; Lynen L; De Jong B; Van Deun A; Decroo T
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
    Souleymane MB; Decroo T; Soumana A; Maman Lawan I; Gagara-Issoufou A; Halidou-Moussa S; Ortuño-Gutiérrez N; Adehossi E; Mamadou S; Van Deun A; Piubello A
    Trials; 2022 Dec; 23(1):1011. PubMed ID: 36514153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
    Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
    [No Abstract]   [Full Text] [Related]  

  • 6. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OTOTOXICITY OF ANTIMYCOBACTERIAL THERAPY: MANIFESTATIONS, MECHANISMS OF MANAGEMENT AND CONTROL.
    Makoyda I; Ostrovskyy М; Shevchuk-Budz U; Molodovets О; Zuban A
    Wiad Lek; 2023; 76(12):2587-2592. PubMed ID: 38290021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.
    Piubello A; Souleymane MB; Hassane-Harouna S; Yacouba A; Lempens P; Assao-Neino MM; Maman-Lawan I; Attaher S; Moustapha B; Soumana A; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Gumusboga M; Hamidou-Harouna Z; Dockx J; Mamadou S; de Jong BC; Decroo T; Van Deun A
    Respir Med; 2020 Jan; 161():105844. PubMed ID: 32056722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
    Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
    J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
    Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
    Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature.
    Swaminathan A; du Cros P; Seddon JA; Mirgayosieva S; Asladdin R; Dusmatova Z
    BMC Infect Dis; 2017 Jun; 17(1):417. PubMed ID: 28606115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France.
    Jaspard M; Butel N; El Helali N; Marigot-Outtandy D; Guillot H; Peytavin G; Veziris N; Bodaghi B; Flandre P; Petitjean G; Caumes E; Pourcher V
    Emerg Infect Dis; 2020 Aug; 26(8):1792-1800. PubMed ID: 32687026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
    Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of bedaquiline-based, modified all-oral 9-11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam.
    Nguyen TMP; Le THM; Merle CSC; Pedrazzoli D; Nguyen NL; Decroo T; Nguyen BH; Hoang TTT; Nguyen VN
    Int J Infect Dis; 2023 Jan; 126():148-154. PubMed ID: 36372364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.
    Mehta S; Das M; Laxmeshwar C; Jonckheere S; Thi SS; Isaakidis P
    PLoS One; 2016; 11(9):e0162138. PubMed ID: 27611434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
    Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
    Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haematological adverse effects associated with linezolid in patients with drug-resistant tuberculosis: an exploratory study.
    Letswee G; Kamau H; Gaida R; Truter I
    Int J Pharm Pract; 2019 Dec; 27(6):575-577. PubMed ID: 31058394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon.
    Mpoh MM; Deli V; Daniel TT; Salvo F
    Int J Mycobacteriol; 2023; 12(2):168-174. PubMed ID: 37338479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.